Vorapaxar in the Treatment of Cardiovascular Diseases

Authors:

Abstract
Vorapaxar specifically and effectively inhibits protease activated receptor-1 and may reduce thrombin-mediated ischemic events without interfering primary hemostasis. In the TRA-2P-TIMI 50 trial, v...

This publication has 37 references indexed in Scilit: